(Q38136262)

29 August 2017

title

Drug safety evaluation of olanzapine pamoate (English)

1 reference

29 August 2017

Daniel Schöttle

1

1 reference

29 August 2017

Olaf Kuhnigk

series ordinal

2

1 reference

29 August 2017

Dieter Naber

series ordinal

3

1 reference

29 August 2017

language of work or name

English

0 references

publication date

12 September 2013

1 reference

Expert Opinion on Drug Safety

29 August 2017

published in

1 reference

29 August 2017

volume

12

1 reference

29 August 2017

issue

6

1 reference

29 August 2017

page(s)

897-903

1 reference

Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.832753

Psychopharmacology: Perspectives on medication adherence and atypical antipsychotic medications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.832753

Improving adherence to antipsychotic pharmacotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.832753

A prospective evaluation of adherence to medication in first episode schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.832753

Insight in schizophrenia: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.832753

Determinants of medication compliance in schizophrenia: empirical and clinical findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.832753

Attitudes toward antipsychotic medication: the impact of clinical variables and relationships with health professionals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.832753

Depot antipsychotic drugs. Place in therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.832753

Antipsychotic medication adherence: is there a difference between typical and atypical agents?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.832753

Profile of olanzapine long-acting injection for the maintenance treatment of adult patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.832753

Olanzapine long-acting injection: a review of its use in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.832753

Long-acting injectable antipsychotics: focus on olanzapine pamoate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.832753

Olanzapine pamoate for the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.832753

Oral versus depot antipsychotic drugs for schizophrenia--a critical systematic review and meta-analysis of randomised long-term trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.832753

Use of depot antipsychotic medications for medication nonadherence in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.832753

Systematic review of patient and nurse attitudes to depot antipsychotic medication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.832753

Attitudes towards long-acting depot antipsychotics: a survey of patients, relatives and psychiatrists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.832753

Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.832753

Effects of olanzapine long-acting injection on levels of functioning among acutely ill patients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.832753

Early response predicts subsequent response to olanzapine long-acting injection in a randomized, double-blind clinical trial of treatment for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.832753

Dose-associated changes in safety and efficacy parameters observed in a 24-week maintenance trial of olanzapine long-acting injection in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.832753

Efficacy of olanzapine long-acting injection in patients with acutely exacerbated schizophrenia: an insight from effect size comparison with historical oral data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.832753

Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.832753

Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.832753

Treatment-completion rates with olanzapine long-acting injection versus risperidone long-acting injection in a 12-month, open-label treatment of schizophrenia: indirect, exploratory comparisons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.832753

D2 receptor occupancy of olanzapine pamoate depot using positron emission tomography: an open-label study in patients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.832753

Comparison of treatment completion rates for olanzapine pamoate and risperidone microspheres.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.832753

Atypical antipsychotics and weight gain--a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.832753

Atypical antipsychotics and hyperglycaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.832753

Psychiatrists' use, knowledge and attitudes to first- and second-generation antipsychotic long-acting injections: comparisons over 5 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.832753

Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.832753

Second-generation antipsychotic long-acting injections: systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.832753

10.1517/14740338.2013.832753

21 January 2018

Identifiers

DOI

1 reference

29 August 2017

1 reference